Overview

Lantus in Prediabetes

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerability, and efficacy of Lantus® (insulin glargine) in prediabetes (IFG or IGT).
Phase:
Phase 1
Details
Lead Sponsor:
Sanofi
Treatments:
Insulin
Insulin Glargine